DE602004013405D1 - Polymorphe formen von valsartan - Google Patents

Polymorphe formen von valsartan

Info

Publication number
DE602004013405D1
DE602004013405D1 DE602004013405T DE602004013405T DE602004013405D1 DE 602004013405 D1 DE602004013405 D1 DE 602004013405D1 DE 602004013405 T DE602004013405 T DE 602004013405T DE 602004013405 T DE602004013405 T DE 602004013405T DE 602004013405 D1 DE602004013405 D1 DE 602004013405D1
Authority
DE
Germany
Prior art keywords
valsartan
polymorph
shapes
crystalline
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004013405T
Other languages
English (en)
Other versions
DE602004013405T2 (de
Inventor
Igor Rukhman
Evgeni Flyaks
Tamas Koltai
Judith Aronhime
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602004013405D1 publication Critical patent/DE602004013405D1/de
Application granted granted Critical
Publication of DE602004013405T2 publication Critical patent/DE602004013405T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE602004013405T 2003-03-17 2004-03-17 Polymorphe formen von valsartan Expired - Fee Related DE602004013405T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45528603P 2003-03-17 2003-03-17
US455286P 2003-03-17
US47364003P 2003-05-28 2003-05-28
US473640P 2003-05-28
PCT/US2004/008322 WO2004083192A1 (en) 2003-03-17 2004-03-17 Polymorphis of valsartan

Publications (2)

Publication Number Publication Date
DE602004013405D1 true DE602004013405D1 (de) 2008-06-12
DE602004013405T2 DE602004013405T2 (de) 2009-05-07

Family

ID=33032685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013405T Expired - Fee Related DE602004013405T2 (de) 2003-03-17 2004-03-17 Polymorphe formen von valsartan

Country Status (7)

Country Link
US (2) US20040242661A1 (de)
EP (1) EP1511739B1 (de)
AT (1) ATE393764T1 (de)
CA (1) CA2519490A1 (de)
DE (1) DE602004013405T2 (de)
ES (1) ES2238022T3 (de)
WO (1) WO2004083192A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
WO2004094392A1 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2005049588A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for isolation of valsartan
EP1661891A1 (de) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto Verfahren zur Herstellung von Valsartan
SI2033629T1 (sl) 2004-12-24 2013-01-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Trden farmacevtski sestavek, ki obsega valsartan
CN101103006A (zh) * 2005-01-11 2008-01-09 特瓦制药工业有限公司 无定形缬沙坦的制备方法
WO2007017897A2 (en) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20070166372A1 (en) * 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
US20080004313A1 (en) * 2006-06-28 2008-01-03 Mai De Ltd. Preparation of crystalline polymorphs of rimonabant hydrochloride
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
SI3067043T1 (sl) 2007-11-06 2023-04-28 Novartis Ag Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
US20110028526A1 (en) * 2008-02-28 2011-02-03 Amol Matharu Valsartan solid oral dosage forms and methods of making such formulations
CN102292072A (zh) 2009-01-26 2011-12-21 特瓦制药工业有限公司 用微粒包衣载体的方法
KR20130139863A (ko) 2010-08-03 2013-12-23 노파르티스 아게 고도 결정질 발사르탄
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2016001844A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Amorphous form of afatinib dimaleate
JP6382736B2 (ja) * 2015-02-02 2018-08-29 株式会社トクヤマ バルサルタンの製造方法
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
US10703728B1 (en) * 2019-06-18 2020-07-07 Scinopharm Taiwan, Ltd. Crystalline form of olaparib and a process for preparing the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
EP0668272B1 (de) * 1994-01-28 2000-07-12 Takeda Chemical Industries, Ltd. Ein Verfahren zur Herstellung von Tetrazolyl-Verbindungen
WO1997030036A1 (en) 1996-02-15 1997-08-21 Novartis Ag Aryl derivatives
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
IT1301759B1 (it) 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
AU2001267404A1 (en) 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
ES2309090T3 (es) * 2000-07-19 2008-12-16 Novartis Ag Sales de valsartan.
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof

Also Published As

Publication number Publication date
US20050222233A1 (en) 2005-10-06
US7105557B2 (en) 2006-09-12
ATE393764T1 (de) 2008-05-15
WO2004083192A1 (en) 2004-09-30
EP1511739B1 (de) 2008-04-30
DE602004013405T2 (de) 2009-05-07
US20040242661A1 (en) 2004-12-02
ES2238022T3 (es) 2008-11-01
EP1511739A1 (de) 2005-03-09
CA2519490A1 (en) 2004-09-30
ES2238022T1 (es) 2005-08-16

Similar Documents

Publication Publication Date Title
DE602004013405D1 (de) Polymorphe formen von valsartan
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
SI1633697T1 (sl) Postopek za pripravo substituiranih 3-aril-butilaminskih spojin
ECSP095220A (es) Derivados de n-fenil-2-pirimidin-amina
TW200615272A (en) Crystalline mycophenolate sodium
MEP15908A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
FR2860224B1 (fr) Solide cristallise im-12 et son procede de preparation
TW200420541A (en) Crystalline forms
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
WO2007119120A3 (en) Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation
FR2855374B1 (fr) Procede de drageification dure ameliore
NO20033408D0 (no) Fremgangsmåte for fremstilling av krystallinske nanopartikler
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
NO20083269L (no) Prosess for a anvende krystallinsk orlistatmetoder
FR2873372B1 (fr) Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
BRPI0605901A (pt) formas polimórficas de maleato de tegaserode
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
FR2858334B1 (fr) Solide cristallise im-11 de type structural lta et son procede de preparation
NO20044332L (no) Forbedret fremgangsmate for fremstilling av nevirapine
IL173447A0 (en) Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee